The original rise of copyright’s flagship product presented a significant chance for shareholders , but its patent has lapsed , creating a intricate landscape. Off-brand versions have entered the arena, eroding profits and putting a strain on profit yields. While leading pharmaceutical companies continue a presence in this area, the outlook remai